Biography
Flavie Naulin is currently a Ph.D. student in the Galluzzi Lab and the Department of Radiation Oncology at the Gustave Roussy Cancer Center (Paris, France), where she investigates PARP7 inhibitors and elevated dose-rates (so-called FLASH radiotherapy) as novel approaches to boost the immunostimulatory effects of radiation therapy in breast and ovarian cancer. Prior to joining the Galluzzi Lab as a Ph.D. Student (2024), she obtained a M.Sc. in Cancerology from the Paris-Saclay University (France; 2024) – involving a 8-month stage with the Galluzzi Lab (2024), after receiving a M.Sc. and a B.Sc. in Health Biology from the University of Montpellier (France; 2023) and the Paris-Saclay University (France; 2019-2022), respectively. Flavie has a long-standing interest in developing novel therapeutic regimens for cancer based on radiation therapy.
(Co)-first Authored Publications
- Bolini, L., Naulin, F., Johnson, N. and L. Galluzzi. Germline BRCA2 mutations foster resistance to CDK4/6 inhibitors in breast cancer. NPJ Precis Oncol, 2026 IN PRESS.
- Guilbaud, E., Naulin, F., Meziani, M., et al. Impact of radiation therapy on the immunological tumor microenvironment. Cell Chem Biol, 2025. 32(5): p. 678-693.
- Naulin, F., Guilbaud, E. and L. Galluzzi. PARP7 and nucleic acid-driven oncosuppression. Cell Mol Immunol, 2024. 21(11): p. 1177-1179.
My Bibliography Link
https://www.ncbi.nlm.nih.gov/myncbi/flavie.naulin.1/bibliography/public/